No connection

Search Results

DOCS vs FOLD

DOCS
Doximity, Inc.
NEUTRAL
Price
$24.01
Market Cap
$4.52B
Sector
Healthcare
AI Confidence
85%
FOLD
Amicus Therapeutics, Inc.
BEARISH
Price
$14.47
Market Cap
$4.54B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
DOCS
20.18
FOLD
--
Forward P/E
DOCS
14.81
FOLD
17.67
P/B Ratio
DOCS
4.54
FOLD
16.41
P/S Ratio
DOCS
7.09
FOLD
7.16
EV/EBITDA
DOCS
15.12
FOLD
111.86

Profitability

Gross Margin
DOCS
89.75%
FOLD
88.5%
Operating Margin
DOCS
38.89%
FOLD
8.61%
Profit Margin
DOCS
37.54%
FOLD
-4.28%
ROE
DOCS
23.82%
FOLD
-11.58%
ROA
DOCS
12.84%
FOLD
2.48%

Growth

Revenue Growth
DOCS
9.8%
FOLD
23.7%
Earnings Growth
DOCS
-16.2%
FOLD
-95.5%

Financial Health

Debt/Equity
DOCS
0.01
FOLD
1.61
Current Ratio
DOCS
6.63
FOLD
2.84
Quick Ratio
DOCS
6.0
FOLD
1.72

Dividends

Dividend Yield
DOCS
--
FOLD
--
Payout Ratio
DOCS
0.0%
FOLD
0.0%

AI Verdict

DOCS NEUTRAL

Doximity exhibits a stable financial foundation with a Piotroski F-Score of 4/9 and an exceptionally clean balance sheet characterized by near-zero debt. Despite elite gross margins (89.75%) and strong liquidity, the company is experiencing a severe valuation correction with a 1-year price decline of 57.4% and negative earnings growth (-16.20%). The current price of $24.01 trades at a significant premium to its Graham Number ($11.91) and Intrinsic Value ($8.33), indicating a disconnect between fundamental defensive value and market pricing. While analyst targets remain bullish, the combination of negative earnings momentum and bearish insider activity suggests caution.

Strengths
Exceptional Gross Margins (89.75%) and Profit Margins (37.54%)
Near-zero leverage with a Debt/Equity ratio of 0.01
Strong liquidity position with a Current Ratio of 6.63
Risks
Negative Earnings Growth (-16.20% YoY and -18.10% Q/Q)
Severe price momentum collapse (-64.1% over the last 6 months)
Bearish insider sentiment with consistent selling by the CFO and Directors
FOLD BEARISH

FOLD exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health and operational deterioration. While the company maintains impressive gross margins (88.5%) and revenue growth (23.7%), these are offset by a catastrophic collapse in earnings growth (-95.5% YoY) and negative ROE. The stock is currently trading at a 52-week high despite a bearish technical trend score (10/100) and aggressive insider selling by the CEO and other officers. The disconnect between the current price and the underlying deterministic health metrics suggests a high risk of a price correction.

Strengths
Exceptional gross margins of 88.50%
Strong year-over-year revenue growth of 23.70%
Robust short-term liquidity with a current ratio of 2.84
Risks
Critically low Piotroski F-Score (2/9) signaling financial instability
Severe earnings growth decline of -95.50% YoY
Heavy insider selling with 11 sell transactions and 0 buys

Compare Another Pair

DOCS vs FOLD: Head-to-Head Comparison

This page compares Doximity, Inc. (DOCS) and Amicus Therapeutics, Inc. (FOLD) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile